Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avandia gets stronger warning

FDA and GlaxoSmithKline (LSE:GSK; GSK) announced Wednesday an agreement to supplement the existing boxed warning for Avandia rosiglitazone to include new language noting that it has been associated with a potential increase

Read the full 320 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE